Trial Search Results
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
To determine the activity of lenalidomide in the treatment of pediatric subjects with relapsed/refractory AML (with second or greater relapse or refractory to at least 2 prior induction attempts) measured by morphological complete response defined as either a CR or CRi within the first 4 cycles of treatment.
Stanford is currently not accepting patients for this trial.
- Drug: Lenalidomide
- Subjects must satisfy the following criteria to be enrolled in the study:
1. Male or female is 1 to ≤ 18 years of age at the time of signing the Informed Consent
Form / Informed Assent Form (ICF/IAF).
2. Subject (when applicable, parental/legal representative) must understand and
voluntarily provide permission to the ICF/IAF prior to conducting any study-related
3. Subject has Relapsed or Refractory Acute Myeloid Leukemia (rrAML) after at least 2
prior induction attempts:
- Bone marrow aspirate or biopsy must have ≥ 5% blasts by morphology and/or flow
- Each block of chemotherapy is a separate reinduction attempt.
- Donor lymphocyte infusion (DLI) is considered a reinduction attempt.
4. Subject is willing and able to adhere to the study visit schedule and other protocol
5. Subject has a Karnofsky score of ≥ 50% (subjects ≥ 16 years of age) or a Lansky score
≥ 50% (subjects < 16 years of age).
6. Subject has a resting left ventricular ejection fraction (LVEF) of ≥ 40% obtained by
7. Subject has recovered from the acute toxic effects of all prior chemotherapy,
immunotherapy, or radiotherapy prior to first dose. All prior treatment-related
toxicities must have resolved to ≤ Grade 2 prior to enrollment.
8. Regarding radiation therapy, time elapsed prior to first dose of lenalidomide:
- 2 weeks for local palliative radiation therapy (XRT).
- 8 weeks if prior craniospinal chemoradiation therapy (CRT) or if ≥ 50% radiation
- 6 weeks if other bone marrow radiation has been administered.
9. Graft-versus-host disease criteria:
- Subject must be at least 2 months (from first dose of lenalidomide) from stem cell
- Subject must have no evidence of active acute or chronic GVHD (Grade 0) for 4 weeks
prior to the first dose of lenalidomide.
- If the subject has a history of maximum Grade 1 or 2 GVHD that was treated with
systemic steroid (≥ 0.5 mg/kg/day prednisone equivalents) or other non-steroid
systemic IST, the subject must be off all IST for at least 2 weeks, and must have
ceased treatment doses of steroids for GVHD (≥ 0.5 mg/kg/day prednisone
equivalents) for at least 4 weeks.
o If the subject has a history of Grade 3 or greater GVHD, the subject must be
off all systemic IST for 4 weeks
o Topical therapy is permitted and does not imply the subject has active acute or
- Physiologic dosing of hydrocortisone is permitted.
10. At least 4 weeks (from first dose) elapsed from donor lymphocyte infusion (DLI)
11. Subject has adequate renal function, which is defined as:
- Creatinine clearance calculated using the Schwartz formula, or radioisotope
glomerular filtration rate (GFR) > 70 mL/min/1.73 m2.
12. Subject has adequate liver function, which is defined as:
• Total bilirubin is ≤ 2 mg/dL unless the increase in bilirubin is attributable to
• AST is ≤ 3.0 x upper normal limit (ULN) for age. For the purpose of this study, the
ULN for AST is 50 U/L.
• ALT is ≤ 3.0 x upper normal limit (ULN) for age. For the purpose of this study, the
ULN for ALT is 45 U/L.
13. Female Children of Childbearing Potential (FCCBP), Female of Childbearing Potential
(FCBP) and male subjects that have reached puberty must agree to undergo
physician-approved reproductive education and discuss the side effects of the study
therapy on reproduction with parent(s) and/or guardian(s).
14. All subjects and/or parents/guardians must have an understanding that lenalidomide
could have a potential teratogenic risk. Female Children of Childbearing Potential,
defined as females who have achieved menarche and/or breast development in Tanner
Stage 2 or greater and have not undergone a hysterectomy or bilateral oophorectomy and
FCBP defined as a sexually mature woman who has not undergone a hysterectomy or
bilateral oophorectomy and has not been naturally postmenopausal for at least 24
consecutive months (ie, has had menses at any time in the preceding 24 consecutive
months) must meet the following conditions below (Note: Amenorrhea following cancer
therapy does not rule out childbearing potential): - Medically supervised serum
pregnancy tests with a sensitivity of at least 25 mIU/mL must be conducted in
FCCBP/FCBP, including those who commit to complete abstinence*. FCCBP/FCBP must have
two pregnancy tests (with a minimum sensitivity of 25 mIU/mL) prior to starting
treatment with lenalidomide. The first pregnancy test must be performed within 10 - 14
days prior to the start of lenalidomide treatment and the second pregnancy test must
be performed within 24 hours prior to starting treatment with lenalidomide.
NOTE: The pregnancy test 10 to 14 days prior to initiation of lenalidomide may be omitted,
at the discretion of the investigator, for any FCCBP/FCBP who has high acuity disease
requiring immediate treatment with lenalidomide. The pregnancy test within 24 hours prior
to the first dose of lenalidomide is required to be performed.
The subject may not receive Investigational Product (IP) until the Investigator has
verified that the results of these pregnancy tests performed on Cycle 1 Day 1 are negative.
FCCBP/FCBP with regular or no menstrual cycles must agree to have pregnancy tests weekly
for the first 28 days of study participation and then every 28 days while on study, at
study Treatment Discontinuation Visit, and at Day 28 following IP discontinuation. If
menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28
days and then every 14 days while on study, at study Treatment Discontinuation Visit, and
at Days 14 and 28 following IP discontinuation.
- Female subjects must, as appropriate to age and at the discretion of the study
Investigator, either commit to true abstinence* from heterosexual contact (which must
be reviewed on a monthly basis) and/or agree to the use of two reliable forms of
approved and effective contraceptive methods simultaneously. The two methods of
reliable contraception must include one highly effective method and one additional
effective (barrier) method (oral, injectable, or implantable hormonal contraceptive;
tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or
vasectomized partner) without interruption, 28 days prior to starting lenalidomide
treatment, throughout the entire duration of study treatment including dose
interruptions and 28 days after the end of study treatment.
- All male and female subjects must follow all requirements defined in the Pregnancy
16. Male subjects, as appropriate to age and the discretion of the study physician:
- Must practice true abstinence* or agree to use a condom during sexual contact with a
pregnant female or a female of childbearing potential while participating in the
study, during dose interruptions and for at least 28 days following lenalidomide
discontinuation, even if he has undergone a successful vasectomy or practices complete
1. Subject has Down syndrome.
2. Subject has French-American-British classification (FAB) type M3 leukemia (acute
promyelocytic leukemia) or identification of t(15;17).
3. Subject has isolated Central Nervous System (CNS) involvement or extramedullary
relapse. (Subjects with combined CNS/marrow relapse may be Subject has had prior
treatment with cytotoxic chemotherapy within 2 weeks of the first dose of lenalidomide
with the exception of hydroxyurea (allowed prior to the first dose of lenalidomide and
through Day 14 of Cycle 1) and intrathecal (IT) cytarabine will be administered within
2 weeks prior to administration of lenalidomide.
5. Subject has had prior treatment with biologic antineoplastic agents less than 7 days
before the first dose of lenalidomide. For agents that have known Adverse Events (AEs)
occurring beyond 7 days after administration (ie, monoclonal antibodies), this period must
be extended beyond the time during which acute AEs are known to occur.
6. Subject has had prior treatment with lenalidomide. 7. Subject is pregnant or lactating.
8. Subject has an uncontrolled systemic fungal, bacterial, or viral infection (defined as
ongoing signs/symptoms related to the infection without improvement despite appropriate
antibiotics, antiviral therapy, and/or other treatment).
9. Subject has known Human Immunodeficiency Virus (HIV) positivity (subjects who are
receiving antiretroviral therapy for HIV disease).
10. Subject has a prior history of malignancies other than AML unless the subject has been
free of the disease for ≥ 5 years from first dose of lenalidomide.
11. The presence of any of the following will exclude a subject from enrollment:
- Subject has any significant medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from participating in the study.
- Subject has any condition including the presence of laboratory abnormalities, which
places the subject at unacceptable risk if he/she were to participate in the study.
- Subject has any condition that confounds the ability to interpret data from the study.
12. Subject has cardiac disorders (Common Terminology Criteria for Adverse Events
[CTCAE] version 4.03 Grade 3 or 4).
13. Subject has a history of well-documented prior veno-occlusive disease (VOD).
14. Subject has any other organ dysfunction (CTCAE version 4.03 Grade 4) that will
interfere with the administration of the therapy according to this protocol.
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study